View Older Stories View More Recent Stories

Jan 3, 2022 04:10PM Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Grants Orphan Drug Exclusivity for Xywav Oral Solution for Idiopathic Hypersomnia in Adults
Jan 3, 2022 04:10PM U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
Dec 30, 2021 07:46AM Jazz Pharmaceuticals (JAZZ) Enrolls First Patient in Phase 2 Clinical Trial Evaluating JZP150 for PTSD
Dec 30, 2021 07:45AM Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
Dec 15, 2021 07:45AM Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
Dec 13, 2021 05:09AM Jazz Pharmaceuticals (JAZZ) Reports Positive Interim Phase 2/3 Results of Rylaze
Dec 13, 2021 04:47AM Jazz Pharmaceuticals (JAZZ) and PharmaMar Initiate Confirmatory Phase 3 Trial of Zepzelca in Patients with Relapsed Small Cell Lung Cancer
Dec 13, 2021 02:30AM PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Dec 12, 2021 09:00AM Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 20
Dec 1, 2021 07:45AM Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting
Nov 30, 2021 08:00AM Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
Nov 9, 2021 04:15PM Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
Nov 9, 2021 04:05PM Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
Nov 4, 2021 11:04AM Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
Oct 26, 2021 04:15PM Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021
Sep 13, 2021 04:15PM Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
Sep 8, 2021 04:15PM Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
Aug 12, 2021 02:32PM Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Approval of Xywav Oral Solution for Idiopathic Hypersomnia in Adults
Aug 12, 2021 02:30PM Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
Aug 10, 2021 08:00AM Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers
Aug 10, 2021 06:38AM Jazz Pharmaceuticals' (JAZZ) GW Unit Receives UK Approval for EPIDYOLEX for Seizures Associated with TSC
Aug 10, 2021 04:24AM GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
Aug 3, 2021 04:05PM Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results
Jul 29, 2021 04:00AM Onera raises €10.5M in Series B funding
Jul 22, 2021 04:15PM National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemi
Jul 21, 2021 09:00AM Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Jul 20, 2021 04:15PM Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021
Jul 13, 2021 04:15PM Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021
Jul 1, 2021 06:16AM Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Approval of Rylaze for Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Jun 30, 2021 08:04PM Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Jun 29, 2021 09:00AM Students awarded scholarships to become agents of change for the epilepsy community!
Jun 25, 2021 07:45AM Jazz Pharmaceuticals (JAZZ) Announces Orphan Drug Exclusivity for Xywav Oral Solution
Jun 25, 2021 07:45AM Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Jun 17, 2021 07:31AM Jazz Pharmaceuticals (JAZZ) Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc
Jun 17, 2021 07:30AM Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc
Jun 14, 2021 07:30AM Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Comm
Jun 9, 2021 07:45AM Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
May 26, 2021 04:15PM Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021
May 20, 2021 07:46AM Jazz Pharmaceuticals (JAZZ) to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio
May 20, 2021 07:45AM Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio
May 10, 2021 06:30AM Bionical Emas launches Expanded Access Program for JZP458 - a recombinant Erwinia Asparaginase
May 5, 2021 09:15AM Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
May 4, 2021 04:15PM Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021
May 4, 2021 04:05PM Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Apr 20, 2021 07:46AM Jazz Pharmaceuticals (JAZZ) Presents Phase 3 Study Results of Xywav Oral Solution in Adult Patients with Idiopathic Hypersomnia at AAN
Apr 20, 2021 07:45AM Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academ
Apr 19, 2021 04:05PM Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021
Apr 12, 2021 07:46AM Jazz Pharmaceuticals (JAZZ) Reports FDA Acceptance and Priority Review of Supplemental NDA for Xywav Oral Solution in Idiopathic Hypersomnia
Apr 12, 2021 07:45AM Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hyp
Mar 31, 2021 06:10AM Jazz (JAZZ) Announces FDA Approval of Additional Indication for Vyxeos for Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
View More Recent Stories View Older Stories